Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Intranasal 5-MeO-DMT in Healthy Subjects
NCT05032833Phase 1Completed
- Sponsor
- Beckley Psytech
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in treatment-resistant depression (TRD) and alcohol use disorder (AUD) comparing 5-MeO-DMT with Placebo (2 arms). Primary endpoint: Percentage of subjects with treatment emergent Adverse Events. Started Sep 2021; status: completed.
02
Drugs
5-MeO-DMT
03
Conditions
treatment-resistant depression (TRD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05032833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032833.